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Abstract
Background: Peripheral intravenous catheters (PIVCs) are ubiquitous medical devices, crucial to providing essential
fluids and drugs. However, post-insertion PIVC failure occurs frequently, likely due to inconsistent maintenance
practice such as flushing. The aim of this implementation study was to evaluate the impact a multifaceted
intervention centred on short PIVC maintenance had on patient outcomes.
Methods: This single-centre, incomplete, stepped wedge, cluster randomised trial with an implementation period
was undertaken at a quaternary hospital in Queensland, Australia. Eligible patients were from general medical and
surgical wards, aged ≥ 18 years, and requiring a PIVC for > 24 h. Wards were the unit of randomisation and allocation
was concealed until the time of crossover to the implementation phase. Patients, clinicians, and researchers were not
masked but infections were adjudicated by a physician masked to allocation. Practice during the control period was
standard care (variable practice with manually prepared flushes of 0.9% sodium chloride). The intervention group
received education reinforcing practice guidelines (including administration with manufacturer-prepared pre-filled flush
syringes). The primary outcome was all-cause PIVC failure (as a composite of occlusion, infiltration, dislodgement,
phlebitis, and primary bloodstream or local infection). Analysis was by intention-to-treat.
Results: Between July 2016 and February 2017, 619 patients from 9 clusters (wards) were enrolled (control n = 306,
intervention n = 313), with 617 patients comprising the intention-to-treat population. PIVC failure was 91 (30%) in the
control and 69 (22%) in the intervention group (risk difference − 8%, 95% CI − 14 to − 1, p = 0.032). Total costs were
lower in the intervention group. No serious adverse events related to study intervention occurred.
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Conclusions: This study demonstrated the effectiveness of post-insertion PIVC flushing according to recommended
guidelines. Evidence-based education, surveillance and products for post-insertion PIVC management are vital to
improve patient outcomes.
Trial registration: Trial submitted for registration on 25 January 2016. Approved and retrospectively registered on 4
August 2016. Ref: ACTRN12616001035415.
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Background
Vascular access via peripheral intravenous catheters
(PIVCs) in the hand or arm is frequently required during
hospital care to administer hydration fluids, medication,
and blood transfusions. An estimated 70% of hospitalised
patients will require a PIVC [1], and a large portion of
these will be inserted and cared for by nurses [2]. Histor-
ically, vascular access device research and practice has
focused on reducing bloodstream infection rates, par-
ticularly in central venous catheters [3]. However,
catheter-related bloodstream infection rates in PIVCs
are extremely low, at 0.03–0.1% [4, 5], or 0.5 per 1000
catheter days [4], whereas PIVC failure rates due to oc-
clusion, infiltration, dislodgement, phlebitis, or infection
are 36% [6].
A failed PIVC is distressing for patients who have to
endure the discomfort of a PIVC complication as well as
the pain associated with a PIVC replacement. Complica-
tions and failure also hold implications for healthcare
budgets with an estimated per-patient cost for PIVC re-
placement of AUD $70 (~ US $50) in 2012 [7], and add-
itional costs associated with an extended hospital stay
due to delayed or interrupted intravenous therapy. With
over two billion PIVCs purchased globally every year [8],
and based on current PIVC complication rates, millions
of dollars are wasted each year through PIVC failure. A
reduction of PIVC failure by just 10% could save signifi-
cant healthcare dollars and reduce unnecessary discom-
fort and risks for patients.
Standards of practice for PIVC maintenance globally
include statements pertaining to flushing for maintaining
patency and function [9, 10]. Flushing the catheter be-
fore and after administration of intravenous medication
creates opportunity for assessment of insertion site and
catheter performance and helps maintain catheter pa-
tency through avoiding mixing of incompatible fluids
and medications, as well as minimising build-up of fibrin
and biofilm that contribute to thrombophlebitis and
catheter dysfunction [9, 11]. However, practice surveys
and observational studies have revealed significant vari-
ation in practice (e.g. use of syringes smaller than 10mL,
use of heparinised saline) and other variations from
guideline recommendations. These inconsistencies and
failure to implement recommended practices likely
contribute to current relatively high PIVC failure rates
[12–14]. Consequently, we developed a multifaceted
intervention to raise awareness of the risks associated
with PIVC use and adherence to guidelines for PIVC
flushing practice. The aim of this study was to evaluate
the effect of a multifaceted intervention that ‘bundled’
reinforcement of PIVC flushing guidelines with
manufacturer-prepared pre-filled flush syringes.
Methods
Study design
This study was a single-centre, sequential, incomplete,
stepped wedge, cross-sectional cluster randomised trial
(SWCRT) with an implementation phase. Clusters
(wards) were randomised for both the control and the
intervention phases. Wards had equal exposure periods
in each phase, rather than for the duration of the study
(incomplete), which helped to avoid the potentially con-
founding impact of different levels of exposure to the
intervention seen in the complete SWCRT design, as
well as minimising the measurement burden [15]. As is
characteristic of the SWCRT designs, each cluster expe-
rienced both control and intervention condition, but
with different participants observed in each phase
(cross-sectional). No data was collected during the im-
plementation (transition) phase when staff received edu-
cation about guidelines and use of pre-filled syringes.
The SWCRT design was chosen over a traditional ran-
domised controlled design due to an inability to minim-
ise contamination between groups if randomising at a
patient level. Further, the SWCRT design was preferred
over the classic parallel-cluster design due to optimised
feasibility and management of staggered rather than en
bloc roll out of intervention [16].
The trial was undertaken at a single metropolitan hos-
pital in Queensland, Australia: the Royal Brisbane and
Women’s Hospital (RBWH) is a 929-bed quaternary and
tertiary referral teaching hospital and the largest pro-
vider of health care services for Queensland Health. The
trial received ethics approval from the Griffith University
(GU Ref No: 2016/052) and the Royal Brisbane and
Women’s Hospital (HREC/15/QRBWH/592) Human Re-
search Ethics Committees. This trial was registered with
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the Australian New Zealand Clinical Trials Registry,
number ACTRN12616001035415.
Participants
Research nurses (ReNs) screened medical and surgical
departments for participants. Patients were eligible if
they were 18 years or older and required a PIVC for clin-
ical treatment for longer than 24 h (with or without con-
tinuous infusion). Non-English-speaking patients without
interpreters and patients who had an existing PIVC-
associated infection were excluded.
Given the intervention was a reiteration of current
practice recommendations and included already licenced
products, no new practice was introduced and no treat-
ment was being withheld; the ethics committees granted
a waiver of consent due to the low/negligible risk associ-
ated with the trial. Patients were given information
sheets about the study being conducted on the ward and
had the ability to opt out if they wished.
Randomisation and masking
Cluster randomisation was performed once at the com-
mencement of the trial using a computer-generated se-
quence (Microsoft Excel), with allocation concealed
(from wards) until each approached the time of cross-
over to the implementation phase. Blinding of patients
and clinical and research nurses was not possible for this
intervention. However, infection outcome was under-
taken by blinded laboratory scientists and infectious dis-
ease specialists.
Procedures
ReNs screened potential patients for eligibility using a
screening tool reflecting the inclusion and exclusion cri-
teria. Recruitment and data collection for the control
period continued until 35 patients were recruited in each
group on each ward. Following the implementation
phase for that ward, data was collected for 4 weeks in
the intervention period until a sample of 35 was ob-
tained. This occurred in a staggered and sequential pat-
tern as per randomisation schedule and schema (Fig. 1).
As per the SWCRT design, the study wards were allo-
cated to both the control and intervention periods. The
control group was the current ‘as usual’ (variable) care.
Practice in the control arm included a combination of
manually prepared syringes with 0.9% sodium chloride
of varying volumes, or infusions from 100mL or 1000
mL 0.9% sodium chloride bags as per clinician prefer-
ence and in variable frequency.
The intervention group received maintenance (flush-
ing) practice according to PIVC flushing guideline rec-
ommendations based on Infusion Nurses Society (INS)
Standards of practice [9] and included manufacturer-
prepared pre-filled flush syringes. The intervention
(Table 1) was centred on raising awareness of the im-
portance of PIVC flushing, reinforcing, and supporting
adherence to current practice recommendations as fol-
lows: assessment of PIVC catheter and site; flushing pre-
and post-medication administration, and also 8 hourly
(as per site-specific guidelines) if the PIVC was not being
used (for infusion or regular medications): use of 0.9%
sodium chloride solution in a single dose manufacturer-
prepared pre-filled syringe (with properties of a 10 mL
Fig. 1 Incomplete stepped wedge cluster randomised trial with an implementation period. Study design and patient flow
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syringe to minimise applied pressure); using a volume
equal to twice the internal volume of the catheter sys-
tem; delivered using a gentle, pulsatile technique; and
documentation. The INS recommendation for initial as-
piration of blood is for central vascular access devices
and is not recommended for PIVCs.
The educational component for the implementation
period was delivered via three sessions a week over a 2-
week period during shift handover (morning/afternoon)
to ensure minimum 80% nursing staff attendance. The
educational component reiterated the current policy and
practice recommendations related to PIVC flushing and
comprised of the following:
(i) Presentation: written guidelines were summarised
for staff in a slide deck at an in-service delivered on
the ward in person and in hard copy. (Reference:
Royal Brisbane and Women’s Hospital 05450/ Proc:
Peripheral Intravenous Cannulation, Venepuncture
and Infusions- Adult and Paediatrics Version 6 Ef-
fective date: 12/2015 Review date: 12/2018.)
(ii) Industry education and demonstration: this entailed a
representative from Becton Dickinson (BD Medical)
educating and training staff on the use of
manufacturer-prepared pre-filled flush syringes used in
the study (Posiflush™, BD Medical, Sandy UT, USA).
(iii)Electronic information: copies of the information
related to the study, as well as slideshow
presentation, and the intervention (guidelines and
pre-filled syringe use) were distributed via a group
email from each ward’s nurse unit manager. Links
to external films were not possible due to firewalls
of the institutional computer networks.
PIVCs were inserted by ward nurses and doctors with-
out the use of ultrasound according to standard operating
procedures. PIVC site, catheter gauge, and attachments
were chosen by the inserter depending on the needs of
each individual patient. Pre-insertion skin disinfection was
done using SoluPrep Swabs (2% chlorhexidine in 70% iso-
propyl alcohol; 3M St Paul, MN, USA). PIVCs were short
(25 to 29.5mm) non-winged Insyte Autoguard BC with
Blood Control Technology (BD Medical). SmartSite
needle-free valves (BD Medical) were connected to PIVCs
directly or via a 10-cm extension set with bonded 3-way
Connecta (BD Medical).
One PIVC was assessed per patient (the first PIVC
inserted after the patient met the inclusion criteria). All
post-insertion care was provided by clinical staff. ReNs
recorded patient and device outcomes and advised staff
about study interventions and products before the study
and during the trial. The decision to remove PIVCs was
made by clinical staff. PIVCs were removed on comple-
tion of therapy, when a complication occurred, or rou-
tinely at 72–96 h of dwell time. Local policy allowed for
dwell time to be extended to more than 96 h if the PIVC
was still required, there were no signs or symptoms of
catheter dysfunction or infection were observed, and the
decision was clinically justified.
ReNs visited patients daily while the PIVC was in place
and followed up on any observed or reported adverse
events. Baseline patient and PIVC characteristics were
recorded. During PIVC dwell, data were collected on
PIVC therapy, insertion site condition, and PIVC per-
formance, e.g. patency. At PIVC removal, ReNs recorded
complications, dwell time, and clinical variables. Forty-
eight hours after PIVC removal, ReNs checked the hos-
pital pathology system for blood, PIVC tip, or insertion
site culture results.
All observations were entered into a secure, portable
electronic device using the REDCap electronic data cap-
ture tools hosted at Griffith University. REDCap (Re-
search Electronic Data Capture) is a secure, web-based
software platform designed to support data capture for
research studies [17]. Clinical staff did not have access
to REDCap. A project manager audited data quality,
completeness, and protocol adherence.
As per routine clinical practice, medical staff ordered
blood, PIVC tip, or site swab cultures if patients were
suspected to have PIVC-associated infections. These
samples were obtained by bedside nurses, processed in
the hospital microbiological laboratory by blinded staff,
and results were accessed by researchers.
Outcomes
The primary outcome was all-cause PIVC failure as a
composite of any unplanned PIVC removal, prior to
completion of therapy. This included occlusion (PIVC
would not infuse, or leakage occurred around the site
when fluid is injected), infiltration (leaking of fluid into
surrounding tissues), dislodgement (complete), phlebitis
(defined by the presence of two or more of the following
symptoms: pain, redness, swelling, and a palpable cord),
and infection (local or laboratory-confirmed blood-
stream infection [3]). A composite measure was chosen
Table 1 Summary of the trial intervention
Education delivered via (i) verbal presentation with slide deck, (ii)
practical demonstration, and (iii) electronic resources.
Guidelines for PIVC flushing
• Assessment of catheter and site
• Pre/post drug administration
• At least Q8h if not in use*
• Use of single-dose manufacturer-prepared prefilled syringe†
• Volume of at least X2 the length and diameter of the catheter‡
• Use of gentle, pulsatile technique
• Documentation of flush (medication or fluid chart)
*As per study site policy
†With properties of 10 mL syringe
‡Except post blood transfusion and some drugs
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as it increases precision and efficiency, as PIVC failure is
the outcome of importance to patients and reduced pa-
tency taking various pathways to the same endpoint [18].
Secondary outcomes were subtypes of PIVC failure
(occlusion, infiltration, dislodgement, phlebitis, and in-
fection), PIVC dwell time (time from insertion to re-
moval), and cost per patient (direct cost to the hospital
for device management, cost of PIVC replacements and
related adverse events). Adverse and serious adverse
events (i.e. death, admission to intensive care, or
laboratory-confirmed bloodstream infection) were moni-
tored using hospital records and reported to the human
research ethics at the study site.
Cost analysis included labour and material costs used
for initial PIVC insertion and staff time taken for this,
cost of flush or infusion products, and additional cost of
follow-on PIVC insertions due to PIVC failure. Details
of the cost analysis are shown in Additional file: Table
S1. Purchase and other costs were collected at 2016
Queensland Health prices in Australian dollars. Mean
total costs and timing for control and intervention prod-
ucts were based on data from an observational study of
infusion and flushing methods we had conducted just
prior to commencement of this trial [14], and also a
comparative study [19]. Costs for nursing and medical
staff time were based on published staff salaries
(Queensland Health 2016) [7]. Staff satisfaction was col-
lected via a study-specific survey on product use as well
as utility and impact of the educational intervention.
The survey comprised six items with an 11-point (mini-
mum 0 to maximum 10) scale and one open-ended
question for free-form text responses.
Statistical analysis
Recent trials showed PIVC failure at the study institu-
tion were approximately 40% using current flushing
practices [5, 20]. An absolute 10% reduction in the
proportion of PIVC failure to 30% was considered both
clinically important and feasible. For a two-sample com-
parison with 90% power, two-sided α level of 0.05, a
sample of 35 patients in each group from 9 wards (35
each ward each group) was required (using the Stata
command ‘steppedwedge’ [21]). The calculation assumed
an intra-cluster correlation coefficient of 0.05 and coeffi-
cient of variation (of clusters) of 0.27 [15]. Thus, the
total sample required was 630.
Data cleaning involved checks of missing, outlier, and
improbable values. Quantitative data was exported into
Stata 15 (Stata-Corp, Texas). Descriptive statistics were
summarised to determine equality at baseline between
study groups. Categorical data were summarised as
counts and proportions, and continuous data as means
and standard deviations. Incidence rates per 1000 cath-
eter days, rate ratio, and log-rank test were presented by
study groups. Univariable Cox regressions were used to
identify potential confounders at the p < 0.20 level. At
this step, the effect of individual wards and their se-
quence were also tested. The potential confounders were
carried forward to the multivariable analysis. Various
analytical approaches were tested, including study group
and cluster treated as fixed effects, interaction between
groups and clusters, and modelling with unobservable
cluster-level random effect. Cox regression with study
group as fixed effect was chosen. Standard errors were
estimated allowing for intragroup correlation (i.e. obser-
vations were independent across clusters but not neces-
sarily within clusters). Potential confounders were
dropped from the multivariable model, in a manual one-
by-one stepwise manner, at p ≥ 0.05. The specification of
the final model was link-tested and the proportional haz-
ard assumption was tested with the Schoenfeld residuals
and the log-log plot of survival. Secondary outcomes
were compared using hypothesis tests. Intention-to-treat
principle was followed. Missing values were not imputed.
Two-tailed p values of < 0.05 were considered as statisti-
cally significant.
A cost analysis was done from the perspective of pub-
lic hospitals, as they are the leading providers of health
care in Australia and main purchasers of PIVCs and
products used for ongoing maintenance. Total resource
use and costs were calculated for each group. The mean
cost of PIVCs was calculated using the Zhao and Tian
host command in Stata [22]. This estimator is appropri-
ate for estimating mean costs that allow adjustment for
censored data. Start times for costs was the date and
time of PIVC insertion. Dwell time was defined as the
interval from the start time until the date and time of
PIVC removal. Costs of insertion were assumed to be
equal between groups as not impacted by intervention
as costed accordingly. The dwell time was censored for
determining the total maintenance and replacement
costs. The incremental net benefit was calculated using
two-stage nonparametric bootstrap sampling for clus-
tered data [23]. Survey data was summarised using
counts and percentages with a simple thematic analysis
of textual data.
Role of the funding source
The funder of the study and education provider had no
role in the study design, data collection, data analysis, or
writing of the manuscript. The corresponding author
has full access to all the data in the study and had final
responsibility to submit for publication.
Results
Between July 2016 and February 2017, we screened 630
patients, and 619 eligible patients were consecutively
enrolled. Reasons for non-participation included the
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following: did not meet inclusion criteria (n = 5), de-
clined (n = 4), and no reason stated (n = 2). Nine wards
participated in the study (306 patients in the control
group and 313 in the intervention group). Computerised
randomisation determined the order of sequential roll-
out. Allocation was concealed until each ward was in the
implementation period. Figure 1 details the list and se-
quence of clusters, as well as the number of participants
by period. Two patients from the intervention group
withdrew, and thus, a total of 617 patients were ana-
lysed. Study ceased when recruitment complete.
A total of 38,712 PIVC dwell hours (1613 days) were
studied, with a mean dwell time 2.6 days (standard devi-
ation [SD] 1.6) which was similar in the study groups.
Clinical and demographic characteristics were also simi-
lar between groups (Table 2).
Ninety-one (30%) patients in the control group experi-
enced PIVC failure compared to 69 (22%) patients in the
intervention group (risk difference: − 8%, 95% CI − 14 to
− 1, p = 0.032). The difference between PIVC failure per
1000 PIVC days was not significant (control 110 [95% CI
89.4 to 135], intervention 87.9 [95% CI 69.4 to 111], inci-
dence rate ratio 0.80 [95% CI 0.58 to 1.11], p = 0.192)
(Table 2).
Other than leakage, no significant differences in the
incidence of occlusion, infiltration, dislodgement, or
phlebitis were identified between groups (Table 2). No
PIVC-related bloodstream infections were reported in ei-
ther group.
The risk of PIVC failure was significantly lower (haz-
ard ratio [HR] 0.78 [95% CI 0.63 to 0.97], p = 0.029) in
the intervention group. Additionally, the use of exten-
sion tubing was associated with a reduction in failure
(HR 0.71 [95% CI 0.57 to 0.87], p = 0.001). Any infection
at baseline was associated with an increased risk of PIVC
failure (HR 1.68 [95% CI 1.1 to 2.58], p = 0.017). The im-
pact of ward sequence on outcome was neutral (HR 1.01
(95% CI 0.88 to 1.14), p = 0.93) (Table 3).
Eight (3%) of 306 patients in the control group and six
(2%) of the 311 patients in the intervention group had
serious adverse events (death [n = 4], intensive care ad-
mission [n = 1], or infection [n = 8]). One patient had
fever of unknown origin with no aetiology recorded.
None of these outcomes was considered to be associated
with study participation.
Cost analysis results are presented in Table 4. The
mean product cost for control group PIVCs was AUD
$13.42 and a staff (time) cost of $7.47. The average costs
for the products and staff were $1.98 and $7.07, respect-
ively, for the intervention PIVCs. The replacement cost
of PIVC was $13 which had been calculated in a previ-
ous study [7]. The overall cost was lower in intervention
group $22.33 (95% CI 22.18 to 22.49, p < 0.001) com-
pared to the control group $33.39 (95% CI 33.28 to
33.50, p < 0.001), with a statistically significant difference
in the total cost between groups of $11.05 (95% CI 10.86
to 11.24, p < 0.001) per patient. The incremental net
benefit calculated was $12.02 (95% CI 11.04 to 12.99).
Ward nurse satisfaction scores were generally high for
both the educational intervention and the use of
manufacturer-prepared pre-filled flush syringes (see
Fig. 2). The majority of nurse respondents indicated that
they found the educational intervention useful in all its
forms (slideshow presentation 48/65, 74% rates ≥ 7;
demonstration 68/80, 85% rated ≥ 7; and written infor-
mation 64/83 77% rated ≥ 7). The majority also stated
that it raised their awareness about flushing guidelines
and policy (62/83, 85% rated ≥ 7). The utility and confi-
dence in the use of manufacturer-prepared pre-filled
flush syringes in practice was also rated highly (80/85,
94% rated ≥ 7 usefulness and 84/85, 99% rated ≥ 7 confi-
dence in use). Results are graphically displayed in Fig. 2.
The main themes emerging from textual responses to an
open question inviting (any) further comment were the
‘time saving’ and ‘convenience’ factor of the manufacturer-
prepared pre-filled flush syringes.
Discussion
This study demonstrated that a multifaceted interven-
tion combining clinical education, reinforcement of
PIVC flushing guidelines, and complementary product
use with manufacturer-prepared pre-filled flush syringes
reduced both the proportion and risk of PIVC failure.
The concept of bundling key steps from lengthy practice
guidelines into a set of point-of-care reminders to im-
prove staff compliance is not new. Following the re-
ported success of central venous access device (CVAD)
bundles [24], a range of PIVC insertion and maintenance
bundles have also been developed and implemented into
practice, in pursuit of similar clinical improvements.
Many studies reported significant reductions in PIVC-
related bloodstream infection, while other studies re-
ported reduced incidence of other PIVC-related compli-
cations (e.g. phlebitis, infiltration) [25]. However, none
of these studies used a randomised design, and standard-
isation was less evident in PIVC studies compared to
CVAD studies. Nevertheless, there is evidence that a
combination approach to interventions or the processes
of care delivery is an advantageous approach that con-
sistently yields improved outcomes compared to single-
entity interventions [25, 26].
Some single-entity intervention studies have reported
improved outcomes, but there are caveats related to
reporting and study design. A systematic review compar-
ing the effectiveness of pre-filled to manually prepared
flushes showed a reduced rate of catheter-related blood-
stream infection (CRBSI) and occlusions, as well as ex-
tending PIVC dwell with the pre-filled group [27].
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Table 2 Baseline demographic and clinical characteristics
Control (n = 306) Intervention (n = 313) Total (n = 619)
Age, yearsa 60 (19) 58 (19) 59 (19)
Sex: males 166 (54) 163 (52) 329 (53)
Diagnosis:
Surgical 164 (54) 168 (54) 332 (54)
Medical 139 (45) 137 (44) 276 (45)
Other 3 (1) 8 (3) 11 (2)
Weight category:
Under 55 (18) 61 (19) 116 (19)
Healthy 151 (49) 160 (51) 311 (50)
Over 87 (28) 79 (25) 166 (27)
Obese 13 (4) 13 (4) 26 (4)
Three of more co morbidities: 164 (54) 171 (56) 335 (54)
Abs. leucocytes < 1000 μL within 72 h 11 (4) 15 (6) 26 (5)
Infection at recruitment 24 (8) 31 (10) 55 (9)
Wound 99 (32) 94 (30) 193 (31)
Good skin integrity 107 (35) 130 (42) 237 (38)
Vein quality:
Good 53 (43) 62 (47) 115 (45)
Poor 69 (57) 71 (53) 140 (55)
Antibiotic therapy at recruitment 153 (50) 125 (40) 278 (45)
IV therapy at recruitment:
Fluids 147 (48) 162 (52) 309 (50)
Intermittent 38 (12) 26 (8) 64 (10)
None 121 (40) 125 (40) 246 (40)
Inserted on dominant side 159 (54) 148 (48) 307 (51)
Inserted by:
Doctor 125 (65) 156 (73) 281 (69)
Nurse 58 (30) 48 (23) 106 (26)
Other 10 (5) 9 (4) 19 (5)
Device location:
Hand 93 (30) 113 (36) 206 (33)
Cubital fossa 80 (26) 68 (22) 148 (24)
Posterior forearm 63 (21) 53 (17) 116 (19)
Wrist 38 (12) 50 (16) 88 (14)
Anterior forearm 30 (10) 25 (8) 55 (9)
Other 2 (1) 4 (1) 6 (1)
Multiple insertion attempts 42 (26) 45 (24) 87 (25)
Skin preparation:
Chlorhexidine 2% with 70% alcohol 118 (89) 149 (96) 267 (93)
Other 14 (5) 6 (2) 20 (3)
Device size (gauge):
22 95 (31) 105 (34) 200 (32)
20 163 (53) 168 (54) 331 (54)
18 47 (15) 40 (13) 87 (14)
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However, the authors stated that these results should be
treated with caution due to poor quality reporting and a
number of limitations with the reviewed studies (e.g.
unit of measurement, lack of core outcome definitions,
heterogeneity). A recent pre- and post-test study ob-
served a decrease in PIVC failure associated with the use
of pre-filled syringes [28]. However, the overall failure
rate even post-intervention remained high (43%) indicat-
ing that there are other drivers at play related to PIVC
failure. In the randomised trial reported in this manu-
script, manufacturer-prepared pre-filled syringes were
part of a whole-of-practice approach to PIVC flushing.
The results of the trial reported in this publication
showed that even with relatively lower complication
rates pre-intervention (30%), streamlining practice and
products related to PIVC flushing yielded significantly
reduced proportion and risk of failure. We demonstrated
that raising awareness about the importance of the
maintenance of vascular access and the techniques to do
this, coupled with products that facilitate adherence with
practice recommendations minimised variation in
practice.
Nursing staff rated the educational intervention and
the use of pre-filled flush syringes highly. The conveni-
ence and time-saving element were frequently cited.
This aligns with previous comparison research [19].
Other possible benefits from the use of manufacturer-
prepared pre-filled flushes that potentially augmented
Table 2 Baseline demographic and clinical characteristics (Continued)
Control (n = 306) Intervention (n = 313) Total (n = 619)
16 53 (43) 62 (47) 115 (45)
Extension tubing 216 (71) 205 (65) 421 (68)
Three-way tap 220 (72) 212 (68) 432 (70)
Frequencies and column percentages shown, unless otherwise noted
abs absolute, μL microlitre
aMean (standard deviation)
Table 3 Study outcomes by treatment group
Control, n = 306 Intervention, n = 311 p value
PIVC failure 91 (30) 69 (22) 0.03
Device-time (accumulative days) 828 785 0.25
Incidence rate per 1000 device days 110 (89.4–135) 87·9 (69.4–111)
Incidence rate ratio Referent 0.80 (0.58–1.11) 0.19
Secondary outcomes:
Occlusion 17 (6) 18 (6) 0.90
Leakage 17 (6) 7 (2) 0.03
Infiltration 40 (13) 32 (10) 0.28
Dislodgement 22 (7) 19 (6) 0.59
Phlebitis (research definition) 20 (9) 11 (5) 0.11
Death 3 (1) 1 (0) 0.30
Positive blood culture 4 (1) 4 (1) 0.98
Cox regression analysis




Study group: intervention 0.81 (0.59–1.11)* 0.78 (0.63–0.97)†
Ward sequence (increase by one) 1.01 (0.88–1.14) $
Infection at baseline 1.68 (1.06–2.66)† 1.68 (1.10–2.58)†
Extension tubing 0.72 (0.52–1.00)* 0.71 (0.57–0.87)†
Frequencies and column percentages shown, unless otherwise noted; p values calculated using chi-squared, rank-sum, or log-rank tests
*p < 0.20
†p < 0.05
aNo other adjustments other than covariate listed
bAdjusted for within-cluster correlation
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the impact of the educational intervention likely relate
to reduced risk of device or solution contamination due
to negated need to draw up solution. Additionally, pre-
filled syringes offer improved medication safety due to
pre-labelling, reduced intra-device reflux due to positive
pressure plunger, reduced risk of cannula or vessel in-
jury (as the syringe has 10 mL properties with appropri-
ate pressure as reflected by pounds per square inch
regardless of volume/syringe size), reduced waste, and
time savings.
Costs were significantly lower in the intervention
group, and staff rated the educational intervention and
use of manufacturer pre-filled flush syringes highly. The
cost analysis for the control group was possibly inflated
by the use of 100 mL bag infusions (as an alternative to
flush delivery). However, this is not unique to this study
setting. The staff time costs were higher in the interven-
tion group when compared to standard practice that did
not employ consistent flushing practice. It is likely that
any small absolute cost difference between manually and
manufacturer-prepared flushes when consistently employed
(as per guidelines) is offset by a reduction in staff prepar-
ation time and lower PIVC failure rate [19]. Given the re-
sults of the study, many of the estimated 10 million PIVC
failures and $175 million in re-siting costs attributed to
these PIVC complications in Australia could be reduced.
Transposing these figures globally where billions of cathe-
ters are used each year [2] underscores the broader and
significant potential for improvement in clinical and
cost-effectiveness associated with improved mainten-
ance practice.
Limitations of this study are related to the single site
setting of the trial and the sampling from medical and
surgical wards. Though this captured some diversity in
patient population (e.g. orthopaedics, respiratory medi-
cine), patients receiving cancer care, critical care, and chil-
dren were not included. This has some implications for
generalisability of findings. Further, the incomplete design
Table 4 Mean costs per patient and cost-effectiveness associated with PIVC maintenance
Control Intervention
Product costsa $13.42 $1.98
Staff timea $7.07 $7.47
Mean maintenance costs $29.60 (28.88–30.32) p < 0.001 $14.84 (14.38–15.31) p < 0.001
Difference in mean costs between intervention and control $14.75 (13.90–15.61) p < 0.001
Cost of replacement PIVCb $13 $13
Mean maintenance and replacement costsc $33.39 (33.28–33.50) p < 0.001 $22.33 (22.18–22.49) p < 0.001
Difference in mean costs between intervention and control – $11.05 (10.86–11.24) p < 0.001
PIVC peripheral intravenous catheter
aStandard deviations were not reported as weighted mean times were calculated
bReplacement PIVCs were required by 91 patients in the control group and 69 patients in the intervention group
cMean cost estimated using hcost program for censored data: Australian Dollar values shown (2016)
Fig. 2 Staff satisfaction rating of intervention % scored ≥ of 7 (out 10)
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did not allow for continued evaluation of outcomes.
Multi-site implementation and evaluation over time would
enhance generalisability and sustainability of the findings.
However, the incomplete design improved the efficiency
of the study and ensured equal exposure of all clusters to
the intervention, minimising the complexity of data ana-
lysis. The stepped wedge design also allowed for a more
manageable and gradual implementation of the study
protocol and data collection.
Conclusions
PIVC outcomes are of high importance considering the
significant level of use and the patient morbidity and
economic burden to hospitals associated with complica-
tions. Research within vascular access has focused on
the reduction of infection; however, the scale and impli-
cations of PIVC failure have only recently been acknowl-
edged. This trial is one of the few recently published
studies addressing the maintenance phase of the PIVC
[20, 29, 30]. It has provided important information on
the effectiveness of post-insertion PIVC maintenance,
specifically, optimising patency through flushing. The
post-insertion phase accounts for approximately 90% of
the episode of vascular access care and is predominantly
in the nursing domain. Important reductions in morbid-
ity and healthcare costs could be achieved if a compre-
hensive post-insertion intervention focused on ongoing
assessment and maintenance could be introduced na-
tionally or worldwide. The impact that the quality of
PIVC maintenance care has on reducing complications
and failure and optimising device duration is significant.
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